Lead Plaintiff Deadline: April 01, 2019
See If You Qualify For Monetary Reward
Please Upload related files below
Fill in below.
Looking for more?
(i) the data from Lexicon’s Phase 3 clinical trials assessing the safety and efficacy of Sotagliflozin in treating type 1 diabetes were not as positive as Lexicon represented; (ii) the health risks posed by Sotagliflozin were severe enough to threaten its U.S. Food & Drug Administration approval prospects; and (iii) as a result, Lexicon’s public statements were materially false and misleading at all relevant times.
In order to be included in the lawsuit, you must have incurred a loss on shares of purchased or acquired during the class period listed above.
If you suffered a loss in during the relevant time frame, you have until April 01, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.